 |
> 1997 Publications
21.
Immunohistochemical expression of Ki-67 to predict lymph node
involvement in clinical stage I non-seminomatous germ cell tumors.
Heidenreich A, Schenkman N, Sesterhenn IA, Mostofi FK, Heidenreich
B, Moul JW:
J Urol, 158:620-625, 1997. |
22.
Clinical Stage I Mature Teratoma of the Testis - Retroperitoneal
Lymphadenectomy or Surveillance?
Heidenreich A, Neubauer S, Mostofi FK, Sesterhenn IA, Moul
JW, Engelmann UH:
Urology 36:440-4, 1997. |
23.
Synchronous Bilateral Testicular-Tumor Nonseminomatous
Germ-Cell Tumors and Contralateral Benign Tumors.
Heidenreich A, Moul JW, Srivastava, S, Engelman UH:
Sci J Urol, N, 31:389-392, 1997. |
24. The role of retroperitoneal lymphadenectomy in patients
with mature teratoma of the testis.
Heidenreich A, Moul JW, McLeod DG, Mostofi FK, Engelmann UH:
Journal of Urology, 157:160-163, 1997. |
25. Gossypiboma (retained surgical sponge) and recurrent
bladder neck contracture following radical retropubic prostatectomy
and bilateral pelvic lymph node dissection.
Heffernan JP, Heidenberg HB, Irby PB, and Moul JW:
J Urol, 157:1356-57, 1997. |
26.
Mutations of the p16 gene product are rare in prostate
cancer.
Gaddipati JP, McLeod DG, Sesterhenn IA, Hussian CJ, Tong YA,
Seth P, Dracopoli NC, Moul JW, and Srivastava S:
The Prostate, 30:188-194, 1997. |
27.
Prostate-specific antigen detected prostate cancer (Stage
T1c): An analysis of whole-mount prostatectomy specimens.
Douglas TH, Sesterhenn IA, Mostofi FK, Moul JW, and McLeod DG:
The Prostate 32:59-64, 1997. |
28.
Effects of adenovirus-mediated p16INK4A expression on
cell cycle arrest are determined by endogenous p16 and Rb status
in human cancer cells.
Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH,
Mudahar B, Srivastava S, Seth P, Cowan K:
Oncogene 16(2):265-272, 1997 |
29.
Benign prostatic hyperplasia (BPH):New concepts in the
1990's.
Bauer JJ, Zorn B, Moul JW:
Fed. Pract. 14(4):24-36, 1997. |
30.
Prostatitis: Diagnostic and treatment challenges.
Bauer JJ, Moul JW.
Fed. Pract. 14:10-15, 1997. |
31.
Biostatistical modeling using traditional variables and genetic
biomarkers for predicting risk for prostate cancer recurrence
after radical prostatectomy.
Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC,
McLeod DG, Srivastava S, Moul JW:
Cancer, 79:952-62, 1997. |
32.
Inhibition of the growth of pre-established subcutaneous
tumor nodules of human prostate cancer cells by single injection
of the recombinant adenovirus p53 expression vector.
Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth
P, and Srivastava S:
Int. J. Cancer, 71:377-382, 1997. |
 Back
to Top |  Previous
Page |
|
